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Inhibition of astrocyte metabolism is 
not the primary mechanism for anaesthetic 
hypnosis
Logan J. Voss1*, Martyn G. Harvey2 and James W. Sleigh3
Abstract 
Astrocytes have been promoted as a possible mechanistic target for anaesthetic hypnosis. The aim of this study was 
to explore this using the neocortical brain slice preparation. The methods were in two parts. Firstly, multiple general 
anaesthetic compounds demonstrating varying in vivo hypnotic potency were analysed for their effect on “zero-mag-
nesium” seizure-like event (SLE) activity in mouse neocortical slices. Subsequently, the effect of astrocyte metabolic 
inhibition was investigated in neocortical slices, and compared with that of the anaesthetic drugs. The rationale was 
that, if suppression of astrocytes was both necessary and sufficient to cause hypnosis in vivo, then inhibition of astro-
cytic metabolism in slices should mimic the anaesthetic effect. In vivo anaesthetic potency correlated strongly with 
the magnitude of reduction in SLE frequency in neocortical slices (R2 37.7 %, p = 0.002). Conversely, SLE frequency 
and length were significantly enhanced during exposure to both fluoroacetate (23 and 20 % increase, respectively, 
p < 0.01) and aminoadipate (12 and 38 % increase, respectively, p < 0.01 and p < 0.05). The capacity of an anaesthetic 
agent to reduce SLE frequency in the neocortical slice is a good indicator of its in vivo hypnotic potency. The results 
do not support the hypothesis that astrocytic metabolic inhibition is a mechanism of anaesthetic hypnosis.
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Background
 Understanding how anaesthetics cause loss of conscious-
ness (hypnosis) is of critical importance to both clinical 
anesthesiologists and neuroscientists—for both safer 
clinical application and understanding the biological 
basis of consciousness. Direct effects on neuronal targets 
are assumed to be involved, however it is interesting to 
note that glia have also been shown to be important tar-
gets for anaesthetic drugs (Jevtovic-Todorovic et al. 2013; 
Rath et  al. 2008; Schummers et  al. 2008; Thrane et  al. 
2012). In particular, Thrane et  al. (2012) have recently 
shown that a chemically diverse group of anaesthetics 
inhibit astrocytic calcium signalling—the basis of astro-
cytic glutamatergic regulation of neuronal synaptic activ-
ity (Parpura and Haydon 2000). The implication is that 
the hypnotic effect of anaesthetics may be due to direct 
inhibitory effects on non-neuronal astrocytic networks.
In vivo models are not ideally suited for disentangling 
anaesthetic hypnotic mechanisms because of the challenge 
of isolating the effects of interest in a controlled fashion. 
In vitro models on the other hand offer the advantage that 
experimental conditions can be manipulated and con-
trolled at will. The isolated brain slice preparation is a case 
in point and has been used extensively to investigate mech-
anisms of anaesthetic effect (Antkowiak and Heck 1997; 
Becker et al. 2012; Ries and Puil 1999; Ying et al. 2006). In 
particular, a range of chemically distinct anaesthetics have 
been shown to have repeatable and robust effects on neo-
cortical field potential dynamics (Voss et  al. 2012, 2013). 
In this study we have taken advantage of these effects to 
investigate whether a disruption to astrocytic networks can 
explain the functional anaesthetic end-point of hypnosis.
The study was carried out in two parts. Firstly, we uti-
lised a range of chemically related ketamine-ester ana-
logues shown to have widely varying in  vivo hypnotic 
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potencies—and identified in cortical slices the field potential 
correlates of the in vivo hypnotic effect. We found that the 
in vivo hypnotic potency of the ketamine-esters correlated 
with their ability to reduce the frequency of zero-magne-
sium seizure-like events (SLEs) in the slice. Propofol and 
etomidate—drugs which are thought to act on a different 
family of receptors to ketamine—were also shown to have 
dose-dependent inhibitory effects on SLE frequency, in 
dose ranges consistent with their relative clinical potencies 
for inducing hypnosis. This is in agreement with previous 
studies (Voss et al. 2012) and indicates that a reduction in 
SLE frequency is the pathognomonic signature of anaes-
thetic hypnotic action in cortical brain slices. With this as 
a basis, we hypothesised in the second part of this paper 
that if astrocyte inhibition is sufficient to cause hypnosis 
during anaesthesia, then inhibition of astrocyte function in 
the cortical slice model should result in a decrease in SLE 
frequency.
Results and discussion
Part 1 results: correlating in vivo hypnotic potency 
with cortical slice electrophysiology
A large range of hypnotic potencies were represented 
in the suite of ketamine-ester analogues, matched by 
equally variable slice SLE responses. Figure  1 plots 
the change in SLE frequency against in  vivo hypnotic 
potency and shows a strong positive correlation (R2 
37.7  %, p  =  0.002)—indicating that the more potent 
hypnotics induced larger reductions in event frequency. 
The correlation was strongly driven by the non-ester 
analogues (R2 = 73 %, p = 0.01, n = 7), confirming that 
the relationship was based largely on drug pharmaco-
dynamics, not the kinetics of ester break-down. Neither 
change in SLE length, nor amplitude correlated signifi-
cantly with hypnotic potency (R2 5.7 and 0.3 %, respec-
tively). The dose-dependent effect of propofol and 
etomidate on SLE frequency (Fig.  2) further indicates 
that the ability of an agent to reduce SLE frequency 
in the cortical slice is a good indicator of its hypnotic 
capacity in vivo. This is consistent with previous investi-
gations showing that clinically used anaesthetics have in 
common the capacity to strongly reduce SLE frequency 
in cortical slices (Voss and Sleigh 2010; Voss et al. 2012). 
We reasoned that if inhibitory effects on astrocytes 
underpinned the ability of anaesthetics to induce hyp-
nosis, then a measurable reduction in SLE frequency 
should be evident following blockade of astrocytic 
metabolism in the cortical slice.
Fig. 1 Scatterplot of the change in seizure-like event (SLE) frequency against in vivo hypnotic potency (mg/kg) for ketamine and each of the 21 
ketamine analogues. Triangles are the non-ester analogues (including ketamine—circled); stars are the ester analogues. The three agents identified 
by arrows that were moderately potent hypnotics but did not induce a reduction in SLE frequency were either seizureogenic or had very rapid 
offset (<100 s)
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Part 2 results: effect of astrocyte inhibition on cortical slice 
SLE activity
Contrary to the main hypothesis, fluoroacetate enhanced 
SLE activity, with no clear dose-dependence. SLE length 
and frequency, respectively, increased on average by 17 
and 10 % for the 1 mM dose (n = 3, 1 animal); 24 and 34 % 
for the 5 mM dose (n = 9, 1 animal, both statistically sig-
nificant increases); and 15 and 16 % for the 10 mM dose 
(n = 5, 1 animal). Thus, the trends were similar across all 
doses. The data were pooled (n = 17, 2 animals) and are 
illustrated in Fig. 3. The possibility of a time-effect should 
be noted for SLE frequency (Voss et  al. 2014), although 
the levelling of this parameter during drug washout sug-
gests at least a part drug effect. SLE amplitude was not 
significantly altered, although the downward trend dur-
ing washout also hints at the possibility of a time effect.
The 0.5  mM dose of aminoadipic had an effect simi-
lar to that of fluoroacetate, with a significant, reversible 
increase in SLE frequency and length (see Figs. 4, 5). The 
1.0 and 5.0 mM doses had biphasic effects, with an ini-
tial excitation (increase in SLE frequency), coupled with 
a reduction in event length and amplitude. SLE activity 
was reversibly silenced at 5.0 mM following a brief surge 
in event frequency. These effects are illustrated in Figs. 4 
and 5.
Prolonged perfusion of 1 mM aminoadipic acid for 2 h 
(n = 3, 2 slices from one animal) consistently and revers-
ibly increased event frequency, with no clear effect on 
either SLE length or amplitude. Thus, the effect of short 
(10 min) and prolonged (2 h) aminoadipic acid perfusion 
were similar.
Aminoadipic acid (1  mM) perfused in normal aCSF 
did not induce SLE activity in three recordings from 
two slices. Zero-magnesium perfusion induced robust 
SLE activity at each of the same three recording loca-
tions, confirming that the slices were viable. Thus, while 
aminoadipic acid had neuroexcitatory effects, it did not 
induce SLE activity unaided.
Combined astrocyte inhibition and anaesthetic exposure
In slices pretreated with 0.5  mM aminoadipic acid, the 
capacity for both propofol (n = 2, 1 animal) and etomi-
date (n = 2, 1 animal) to strongly reduce SLE frequency 
remained intact.
Results summary
The aim of this study was to investigate whether the hyp-
notic action of NMDA antagonist and GABA agonist 
general anaesthetics could be explained by cerebrocor-
tical suppression of astrocyte function. To this end, we 
first sought to identify in cortical slices a robust correlate 
of in  vivo hypnotic potency—and found that the magni-
tude of the reduction in SLE frequency in slices correlated 
well with the ability of each test drug to induce hypnosis 
in vivo. With this as a comparator, we then determined the 
effect of astrocyte metabolic inhibition on cortical slice 
SLE activity. We reasoned that if anaesthetic suppression 
of astrocyte activity mediates the hypnotic action of these 
drugs, then targeted astrocyte inhibition in slices should 
be apparent as a reduction in SLE frequency. This was 
clearly not the case—we observed the opposite effect, with 
enhancement of SLE activity for both pharmacologically 
distinct astrocyte inhibitors. Additionally, if astrocyte sup-
pression explains anaesthetic hypnosis, we might expect a 
profound synergy between astrocytic metabolic inhibitors 
and the response to propofol and etomidate, which was 
not observed. Accordingly, our results do not support the 
Fig. 2 Graphs showing the effect of sequentially higher doses of 
a etomidate (n = 18) and b propofol (n = 28) on the frequency of 
seizure-like event frequency. Each dose was perfused for 30 min 
or until SLE frequency reduced by at least 50 % compared to the 
baseline value. The data are normalised to the baseline frequency 
and are expressed as mean + SEM. *p < 0.001, compared to baseline, 
Friedman Test with Dunn’s Multiple Comparisons
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Fig. 3 Effect of fluoroacetate (F-acetate) (combined doses 1, 5 and 10 mM) on seizure-like event (SLE) a length, b frequency and c amplitude 
(n = 17). The data are normalised to the baseline values and are expressed as mean + SEM. *p < 0.05, compared to baseline, Friedman Test with 
Dunn’s Multiple Comparisons. **p < 0.01, compared to baseline, Friedman Test with Dunn’s Multiple Comparisons
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hypothesis that suppression of astrocytes is a mechanism 
of anaesthetic hypnosis. While the experimental design 
of this study indirectly probed the relationship between 
anaesthetic effects on astrocytes and anaesthetic hypnosis, 
the logic is clear—if hypnotic anaesthetic action is robustly 
associated with suppression of SLEs; and astrocyte inhi-
bition has the opposite effect; then astrocyte inhibition is 
unlikely to be a major component contributing to anaes-
thetic hypnosis.
Excitatory effects of astrocyte inhibition
The mechanism of enhanced population activity fol-
lowing astrocytic inhibition is likely to be multimodal. 
For the dose range of aminoadipic acid applied in this 
study, the predominant effects are likely to be inhibition 
of Na-dependent glutamate re-uptake (McBean 1994; 
Tsai et al. 1996) and reduced kynurenic acid production 
(Gramsbergen et al. 1997; Wu et al. 1995). A 65 % reduc-
tion in glutamate uptake is seen in cultured rat astrocytes 
at 0.5 mM aminoadipic acid (Tsai et al. 1996). Kynurenic 
acid is an endogenous excitatory amino acid receptor 
inhibitor, meaning reduced production will have a neu-
roexcitatory effect. Aminoadipic acid 0.5  mM applied 
to thick (1  mm) neocortical sections for 2  h reduces 
kynurenic acid production by 60  % (Gramsbergen et  al. 
1997), an effect specifically mediated by astrocytes (Wu 
et al. 1995). Aminoadipic acid could also cause astrocyte-
dependent neuroexcitation by inhibition of glutamine 
synthetase activity (mediating the astrocytic conversion 
of glutamate to glutamine) and by inhibition of gamma-
glutamylcysteine synthetase (mediating astrocytic syn-
thesis of glutathione)—however at the dose and duration 
of exposure in the current study these effects are prob-
ably negligible (McBean 1994; Tsai et al. 1996).
Fig. 4 Effect of 0.5 (n = 17), 1.0 (n = 13) and 5.0 mM (n = 8) aminoadipic acid on seizure-like event a frequency, b length and c amplitude. The 
data are normalised to baseline values and are expressed as mean + SEM. *p < 0.05, compared to baseline, Friedman Test with Dunn’s Multiple 
Comparisons. **p < 0.01, compared to baseline, Friedman Test with Dunn’s Multiple Comparisons
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Fig. 5 Examples from three slices showing the effect of a 0.5 mM, b 1.0 mM and c 5.0 mM aminoadipic acid on seizure-like event (SLE) characteris-
tics. In each plot, the individual vertical lines represent single SLE events. The thumbnail inserts show zoomed sections from the corresponding time 
points in the main figure
Page 7 of 10Voss et al. SpringerPlus  (2016) 5:1041 
The mechanism of effect of fluoroacetate is likely to 
overlap with aminoadipic acid. When applied to rat hip-
pocampal slices for 1–2.5 h, 1 mM fluoroacetate results 
in an increase in stimulation-induced overflow of extra-
cellular glutamate, providing an adequate supply of glu-
tamine (glutamate precursor) is maintained (Szerb and 
Issekutz 1987). The reduction in glutamate up-take by 
astrocytes is probably due to a reduction in the activity of 
the Na pump, secondary to tricarboxylic acid cycle inhi-
bition and reduced ATP production (Szerb and Issekutz 
1987). The similarity of effects on SLE activity of fluoro-
acetate and low-dose L-alpha-aminoadipic acid in our 
study can therefore be explained by similar functional 
end-points.
Methodological considerations
Astrocytes are acutely sensitive to general anaesthet-
ics, at concentrations below that necessary to effect sig-
nificant changes in neuronal activity (Schummers et  al. 
2008). Collectively, the documented effects are inhibitory, 
including impaired glutamate uptake (Rath et  al. 2008), 
reduction in calcium signalling (Schummers et  al. 2008; 
Thrane et al. 2012) and reduced glial fibrillary acidic pro-
tein staining (Jevtovic-Todorovic et  al. 2013). In other 
words, anaesthetics broadly inhibit astrocytic function. It 
was upon this basis that we applied metabolic blockers to 
mimic anaesthetic suppression of astrocyte function.
Interpretation of the findings of this study depends 
critically on posology. A dose of 45  µg/ml was chosen 
for all remiketamine variants on the basis of pilot experi-
ments (data not shown) in which this dose was shown 
to effect changes in SLE parameters similar to that pre-
viously investigated for other anaesthetics (Voss et  al. 
2012). A higher dose than previously used for ketamine 
(4 µg/ml; Voss et al. 2012) was necessary because the ket-
amine analogues are rapidly deactivated by tissue ester-
ases (Harvey et al. 2015).
The drug dose ranges for propofol and etomidate were 
chosen to be clinically relevant, based on previous stud-
ies investigating the diffusion characteristics of etomidate 
into brain slice tissue (Benkwitz et al. 2007) and the rela-
tive in  vivo potencies of etomidate and propofol (Avra-
mov et al. 1995). Briefly, in 400 µm slices, the etomidate 
concentration at a depth of 100–200 µm approaches 50 % 
of the concentration in the bath within approximately 
20 min (Benkwitz et al. 2007). For the lowest etomidate 
dose in our study (8  µM) this would equate to a tissue 
concentration of 4  µM at the end of the 30  min deliv-
ery period. An effect-site etomidate concentration of 
2  µM renders 50  % of rats anaesthetised and 4–12  µM 
equates to deep anaesthesia (De Paepe et  al. 1999). The 
dose ranges for sodium fluoroacetate and aminoadipic 
acid were based on previous investigations utilising the 
same drugs in similar in  vitro preparations (Benjamin 
and Verjee 1980; Charles and Chang 1983; Cheng et  al. 
1972; Haugstad and Langmoen 1997; Saito 1990). At 
the highest dose of aminoadipic acid (5  mM), a strong 
inhibition to SLE activity was observed. We believe this 
was the result of a direct neuronal effect, based on four 
observations:
1. The aminoadipic acid LD50 in glial cultures is 
approximately 0.6 mM (Bridges et al. 1992).
2. In cultured cerebellar cells, aminoadipic acid is toxic 
to both neurons and glial cells at 1.5 and 5.0  mM 
(Garthwaite and Regan 1980).
3. 3  mM aminoadipic acid applied to striatal slices 
results in neuronal degeneration, while no neuronal 
effect is seen when administered at 1 mM for 40 min 
(McBean 1990).
4. Aminoadipic acid at 0.5 mM in the present study had 
effects on SLE activity that were qualitatively identi-
cal to that of fluoroacetate (1–10 mM)—while fluoro-
acetate does not directly affect neuronal excitability 
following 5 mM application to rat cortical slices for 
40 min (Fossat et al. 2012).
Our conclusion is that astrocyte-specific effects pre-
dominate in the 0.5–1.0 mM dose range for aminoadipic 
acid and that the excitatory effects seen at 0.5 and 1.0 mM 
can be interpreted accordingly. The alternate possibility 
of a weak direct neuroexcitatory effect of aminoadipic 
acid via glutamate receptors cannot be completely ruled 
out (McLennan and Hall 1978). Aminoadipic acid is 
only 15 % as potent as L-glutamate (McLennan and Hall 
1978). The similarity of response in the present study 
between that of fluoroacetate (which does not directly 
affect neurons) and 0.5  mM aminoadipic acid indicates 
that a direct neuroexcitatory effect at this low dose is at 
best negligible.
Conclusion
In conclusion, the results of this study fail to support the 
underlying hypothesis that astrocytic inhibition causes 
anaesthetic hypnosis. A role for astrocytes in limiting 
neuroexcitation is identified.
Methods
For the in  vivo study, adult Sprague–Dawley rats were 
obtained from the Ruakura Animal Research Centre, 
Hamilton, New Zealand, with approval from the Ruakura 
Animal Ethics Committee. For the in vitro cortical slice 
study, adult mice (C57/BL6/129SV) were obtained from 
a breeding colony at Waikato University, Hamilton, New 
Zealand, with approval from the Waikato Animal Ethics 
Committee.
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The methods were divided into two parts.
Part 1: correlating in vivo hypnotic potency with cortical 
slice electrophysiology
In vivo analysis of anaesthetic hypnotic potency
The in vivo analysis of the hypnotic potency of 21 keta-
mine analogue compounds has been reported in part 
elsewhere (Harvey et  al. 2015; Jose et  al. 2013). The 
results form part of a wider screening investigation pur-
suing the development of ketamine-ester analogues with 
rapid offset characteristics via hydrolysis of pharma-
cologically active ester groups. This set of compounds 
included seven non-ester entities (including ketamine), 
but for simplicity we will retain the term “ketamine-
esters” to describe the collective group. For the purpose 
of this study, these ketamine-ester variants provided 
a range of structurally similar compounds with vary-
ing hypnotic potencies—which could be correlated with 
their effect on cortical slice field potential activity.
The methodology of drug design, synthesis and test-
ing has been detailed previously (Harvey et  al. 2015; 
Jose et  al. 2013). In brief; adult female Sprague–Dawley 
rats (n = 3 per agent) were non-traumatically restrained 
and the marginal vein of the tail cannulated. One of 21 
ketamine-ester analogues was delivered at 10 mg/ml via 
a minibore extension tube secured to the tail. Weight-
adjusted infusions were administered at 20  mg/kg/min 
initially and continued until the animal lost both its abil-
ity to maintain righting, and attenuated its withdrawal 
response to firm digital pressure on the forepaw. There-
after, the infusion rate was reduced to 6.7 mg/kg/min and 
adjusted in an up-and-down fashion to maintain dorsal 
recumbency for 10 min, before cessation. The dose (mg/
kg) to loss of righting was adopted as a measure of effec-
tive hypnotic potency.
Cortical slice electrophysiology
Cortical slice preparation Cortical slices were prepared 
from adult mice of either sex. The animals were anaesthe-
tised with carbon dioxide prior to decapitation and brain 
dissection. The cerebrum was placed into ice-cold carbo-
genated (95 % O2; 5 % CO2) artificial cerebrospinal fluid 
(aCSF) containing: 92.7  mM NaCl, 3  mM KCl, 19  mM 
MgCl2, 0 mM CaCl2, 1.2 mM NaH2PO4, 24 mM NaHCO3 
and 25 mM d-glucose (Nowak and Bullier 1996). Coronal 
slices (400 µM) were cut between Bregma −1 to −5 mm 
on a vibratome (Campden Instruments, UK) and trans-
ferred to a holding bath with carbogenated aCSF contain-
ing zero magnesium (124 mM NaCl, 5 mM KCl, 2 mM 
CaCl2, 1.25 mM NaH2PO4, 26 mM NaHCO3 and 10 mM 
d-glucose). The slices were left undisturbed for at least an 
hour prior to recording at room temperature (approxi-
mately 28 °C).
Electrophysiology recording parameters and  experimen-
tal procedure One slice at a time was transferred to a 
recording bath (Tissue Recording System, Kerr Scientific 
Instruments, New Zealand) perfused with carbogenated 
zero-magnesium aCSF at a gravity-fed flow rate of 6.0 ml/
min. Removal of magnesium ions from the aCSF activates 
the cortical tissue, resulting in spontaneous field potential 
activity resembling short seizure-like events (SLEs) that 
can be recorded unabated for several hours (Voss and 
Sleigh 2010). Field potentials were recorded using Teflon-
coated (50 µm) tungsten electrodes, referenced to a silver/
silver-chloride electrode located in the recording bath. Up 
to four recording electrodes were positioned equidistant 
apart in the cerebral cortex, with no particular cortical 
location targeted. The data was recorded with a 1000× 
gain, low- and high pass filtered at 1000 and 1.0 Hz respec-
tively (Model 1800 AC amplifier, A-M Systems, USA) and 
sampled at a frequency of 5000 samples/second (Power 
1401, Cambridge Electronic Designs, UK). Recordings 
were saved for analysis using Matlab (Version 7.3.0.267 
(R2006b), The Mathworks Inc., Natick, MA, USA).
Testing ketamine variants in  cortical slices Recordings 
were made from 24 slices from 6 animals. SLE activity 
was recorded for at least 10  min to achieve a baseline. 
Thereafter, one of the ketamine-ester test agents was 
perfused at 45 µg/ml for 20 min followed by drug wash-
out for 20  min with drug-free zero-magnesium aCSF. 
All agents were tested at the same dose. On eight occa-
sions, two or three agents were tested in the same slice, 
in which case sufficient time was allowed for SLE activ-
ity to return to baseline levels before perfusing the next 
drug. Where multiple electrodes were positioned in the 
same slice, each channel was considered an independent 
recording on the condition that SLE activity was not cou-
pled between locations. The basis of this proviso is that 
neocortical SLE activity can be generated from multiple 
independent locations within the same slice, just as if the 
slice was physically sectioned between recording loca-
tions (Voss et al. 2012).
Testing propofol and etomidate in cortical slices In addi-
tion to the ketamine variants, dose response characteris-
tics of propofol and etmoidate, two established general 
anaesthetics, were quantified in cortical slices. For propo-
fol, 28 recordings were made from 20 slices (10 animals) 
and for etomidate, 18 recordings were made form 14 slices 
(9 animals). Following at least 10  min of baseline SLE 
recording, one or other drug was perfused at 3 sequential 
doses (28, 56 and 84 µM for propofol and 8, 16 and 24 µM 
for etomidate). Each dose was applied for 30 min in a step-
wise manner until either the maximum dose was reached 
or the SLE frequency reduced to <50 % of that established 
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during baseline. Thereafter, washout with zero-magne-
sium aCSF was continued for 40 min.
Data analysis
For the ketamine-esters, the drug effect on SLE fre-
quency, length and amplitude was quantified as the mean 
percent change in each parameter from baseline relative 
to the 15–20 min period towards the end of drug perfu-
sion. This period represents the time at which the drug 
was at peak concentration within the slice bath, tak-
ing into consideration the initial wash-in period. The 
in  vivo hypnotic potency [the dose (mg/kg) to loss of 
righting] for each variant was related to its effect on SLE 
frequency, amplitude and length. Linear regression was 
used to quantify the relationship between in  vivo hyp-
notic potency and change in each SLE parameter.
For the propofol and etomidate experiments, SLE fre-
quency was normalised to baseline and averaged over three 
30 min time periods corresponding to each drug dose (off-
set by 10  min to the start of each dose to allow for drug 
equilibration in the perfusion bath) and a washout period 
at the end of the recording. If the second or third dose was 
not delivered (because SLE frequency had already reduced 
by more than 50 %), for that recording the frequency was 
assumed to be zero for the analysis of those time periods.
Part 2: testing astrocytic metabolic inhibition on cortical 
slice SLE activity
The methods for cortical slice preparation and electro-
physiological recording of zero-magnesium SLE activity 
were as described above.
Two astrocyte metabolic inhibitors were tested, fluoro-
acetate and aminoadipic acid. Fluoroacetate was deliv-
ered in three concentrations, 1, 5 and 10 mM. The pH of 
the 5  mM solution was 7.52 and was not adjusted. The 
pH of the 10 mM solution was 7.74 and was adjusted to 
7.58 with 0.1 M HCl. The osmolarity of the 10 mM solu-
tion was adjusted to the equivalent of 5 mM by reducing 
the NaCl concentration in solution by 5 mM. All fluoro-
acetate concentrations were run for 45 min, followed by 
drug washout for 40 min. The effects were similar across 
all concentrations, therefore the data was pooled. For 
statistical analysis, SLE amplitude, length and frequency 
were averaged for each slice over three broad epochs: the 
7  min period prior to drug delivery; the 45  min period 
of drug delivery; and the first 20  min period of drug 
washout. Because the data was not normally distributed 
(Kolmogorov and Smirnov test), the three epochs were 
compared statistically using non-parametric repeated 
measures ANOVA (Friedman test).
Aminoadipic acid was delivered in 3 concentrations, 
0.5 (n = 17 from 3 animals), 1.0 (n = 13 from 2 animals) 
and 5 mM (n = 8 from 2 animals). The pH of the 1 mM 
solution was 7.54 and was not adjusted. The pH of the 
5  mM solution was 7.2 and was adjusted to 7.58 with 
0.1 M NaOH for three slices. The effect was qualitatively 
identical whether pH was adjusted or not and the data 
was therefore pooled. The 0.5  mM solution was run for 
15 min, the 1 mM solution for 10 min and the 5 mM solu-
tion for 7 min, followed by drug washout. SLE amplitude, 
length and frequency were averaged for each slice over 
seven 100 s epochs, one during baseline recording 3 min 
before start of drug infusion and six sequential epochs 
from the start of drug infusion. This enhanced time res-
olution was necessary because aminoadipic acid had 
multiple effects both within and between the three con-
centrations tested. Because the data was not normally dis-
tributed (Kolmogorov and Smirnov test), the epochs were 
compared statistically using non-parametric repeated 
measures ANOVA (Friedman test). Only statistical com-
parison to the baseline epoch is reported. In three cases 
for the 5 mM dose, recording was terminated immediately 
after SLE activity ceased. It was assumed in these cases 
that SLE activity would have continued suppressed for the 
remaining epochs under analysis, in keeping with the data 
from the slices in which recording was continued.
Combined astrocytic metabolic inhibition and anaesthetic 
delivery
To confirm whether the anaesthetic effect on SLE fre-
quency persisted during astrocytic metabolic inhibi-
tion, in two recordings each for propofol and etomidate, 
slices were pretreated with 0.5  mM aminoadipic acid 
for 15 min before anaesthetic perfusion (84 and 24 µM, 
respectively). When SLE frequency had reduced to at 
least half of the baseline frequency, aminoadipic acid and 
anaesthetic were washed out with drug-free zero-magne-
sium until SLE activity returned.
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